ArticlePhysiological reports2026
Mass spectrometry-based urinary proteomic analysis in feline chronic kidney disease.
Article in Physiological reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mass spectrometry-based urinary proteomic analysis in feline chronic kidney disease.Physiological reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Chronic kidney disease (CKD) is highly prevalent in domestic cats (Felis catus), which might serve as a spontaneous disease model for human CKD. Urinary proteomics is a promising tool for CKD diagnosis and management; yet, minimal information is available in cats. This study aimed to explore the urinary proteome in cats with CKD and assess its diagnostic value. High-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) was used for proteomic analysis, and protein quantities were calibrated to a spike-in internal standard. A cohort of 37 cats (14 with surgically induced CKD, 23 healthy controls) was used as a training dataset; a separate cohort of 40 cats (23 cats with naturally occurring CKD, 17 healthy controls) was used as the test dataset. A random forest model showed an area under the receiver-operating-characteristic (ROC) curve of 0.982 (95% CI, 0.952-1.000), outperforming serum symmetric dimethylarginine (SDMA) concentration, urinary protein-to-creatinine ratio, and other commonly studied urinary biomarkers (i.e., transferrin, albumin, and cystatin C). Retinol-binding protein 4 (RBP4) achieved a comparable area under the ROC curve of 0.957 (95% CI, 0.885-1.000). These data provide proof of concept for a mass spectrometry-based urinary proteomic analysis in feline CKD and identified urinary RBP4 as a CKD biomarker in cats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.